Lenabasum Use Seen to Lessen Inflammation, Fibrosis in Phase 2 dcSSc Trial
Treatment with lenabasum is safe and leads to clinically meaningful improvements in people with diffuse cutaneous scleroderma (dcSSc), results from Phase 2 trial show. The therapy is now being tested in this trial’s extension study, as well as in a Phase 3 trial in adults with dcSSc.